Last reviewed · How we verify
AG0301-COVID19
At a glance
| Generic name | AG0301-COVID19 |
|---|---|
| Sponsor | AnGes, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of COVID-19 DNA Vaccine (AG0301-COVID19) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AG0301-COVID19 CI brief — competitive landscape report
- AG0301-COVID19 updates RSS · CI watch RSS
- AnGes, Inc. portfolio CI